Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy

BACKGROUND: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long-term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. METHODS: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno-associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail-cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension-associated comorbidities were examined through histological analysis and ELISA. A modified N-acetylgalactosamine-conjugated small interfering RNA targeting human hepatic AGT (GalNAc-siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. RESULTS: The dual adeno-associated virus-induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc-siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc-siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio- and renoprotective effects. Moreover, combining GalNAc-siAGT with the renin-angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. CONCLUSIONS: Our study validated the antihypertensive therapeutic effect of GalNAc-siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-11-12
DOI
https://doi.org/10.1161/jaha.125.046444
Primary Topic
Renin-Angiotensin System Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy

Xiaoling Guo, Tingting Liu, Junhao Xiong, 吴连拼 et al.
Journal of the American Heart Association
Renin-Angiotensin System Studies
article

Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy

Xiaoling Guo, Tingting Liu, Junhao Xiong, 吴连拼, Dan Zhu, Bing Zhang, Kang Cheng, Ruogu Li, Juntao Lin, Shasha Zhang, Yuanzhe Sheng, Xing Liu
article en

Abstract

BACKGROUND: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long-term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. METHODS: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno-associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail-cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension-associated comorbidities were examined through histological analysis and ELISA. A modified N-acetylgalactosamine-conjugated small interfering RNA targeting human hepatic AGT (GalNAc-siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. RESULTS: The dual adeno-associated virus-induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc-siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc-siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio- and renoprotective effects. Moreover, combining GalNAc-siAGT with the renin-angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. CONCLUSIONS: Our study validated the antihypertensive therapeutic effect of GalNAc-siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.

Journal of the American Heart Association
Shanghai Jiao Tong University (CN), Shanghai Chest Hospital (CN), Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
Good health and well-being
Renin-Angiotensin System Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon